Horizon 2020

Giornate Nazionali
di lancio dei bandi
Work Programme 18-20

(SC1), Health, demographic change and well-being
Giornata Nazionale di Lancio dei Bandi 2018-20 in Horizon 2020

Roma, 15 Dicembre 2017
Sapienza Università di Roma, Aula Magna, Piazzale Aldo Moro, 5

Nuove iniziative nella programmazione e partecipazione italiana nella Sfida per la Società 1 in Horizon 2020

Angela Santoni
Dipartimento di Medicina Molecolare

ISTITUTO PASTEUR ITALIA
FONDAZIONE CENCI BOLOGNETTI
The challenges

- Ageing population
- Increased disease burden
- Unsustainable and unequal health & care systems
- Health & care sector under pressure to reform
Health, demographic change and wellbeing challenge (SC1) - DG R&I and DG CNECT -

Less prescription – what to do, but not how to do it

Strengthening competitiveness of EU industries – development of new market opportunities

Multidisciplinary approach - fostering cooperation between academic and industrial sectors
RISULTATI COMPLESSIVI 2014 / 2017

SC1 – Health, demographic change and Wellbeing
### PHC - Bando 2014-2015

<table>
<thead>
<tr>
<th>No. topics</th>
<th>Budget Mill. EUR</th>
<th>Proposte presentate</th>
<th>Proposte finanziate</th>
<th>Tasso di successo</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>1031,7</td>
<td>2253</td>
<td>180</td>
<td>8%</td>
</tr>
</tbody>
</table>

#### Partecipazione

<table>
<thead>
<tr>
<th>Partecipazione italiana in proposte presentate</th>
<th>Partecipazione italiana finanziate</th>
<th>Tasso di successo partecipanti Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>2470</td>
<td>181</td>
<td>7%</td>
</tr>
</tbody>
</table>

(*) Con partecipazione, si intende la partecipazione sia a coordinamento sia come partner.

#### Coordinamento

<table>
<thead>
<tr>
<th>No. Proposte presentate a coordinamento italiano</th>
<th>No. Coordinamenti italiani finanziati</th>
<th>Tasso di successo coordinatori Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>311 (14% del totale EU)</td>
<td>15</td>
<td>4,8%</td>
</tr>
</tbody>
</table>

### Bandi 2014-2015-2016-2017

*dati aggiornati a Ottobre 2017*

<table>
<thead>
<tr>
<th>No. topics</th>
<th>Budget Mill. EUR</th>
<th>Proposte presentate</th>
<th>Proposte finanziate</th>
<th>Tasso di successo</th>
</tr>
</thead>
<tbody>
<tr>
<td>62</td>
<td>2939,3</td>
<td>3373</td>
<td>343</td>
<td>10%</td>
</tr>
</tbody>
</table>

#### Partecipazione

<table>
<thead>
<tr>
<th>No. Partecipanti italiani in proposte presentate</th>
<th>No. Partecipanti italiani finanziati</th>
<th>Tasso di successo partecipanti Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>3716</td>
<td>369</td>
<td>9,9%</td>
</tr>
</tbody>
</table>

#### Coordinamento

<table>
<thead>
<tr>
<th>No. Proposte presentate a coordinamento italiano</th>
<th>No. Coordinamenti italiani finanziati</th>
<th>Tasso di successo coordinatori Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>459 (13% del totale EU)</td>
<td>26</td>
<td>5,6%</td>
</tr>
</tbody>
</table>
La partecipazione Italiana a Horizon 2020

La fotografia a metà percorso

Figura 27 - Regioni: confronto n. partecipazioni eligible/retained e tasso di successo

*Dati aggiornati a Settembre 2016*
Horizon 2020 Advisory Group for SC1, "Health, Demographic Change and Well-being" WP 2018-2020

The main research priorities

**VERTICAL themes**

1. Personalised medicine
2. Rare diseases
3. Infectious diseases
4. Non-communicable diseases
5. Paediatrics
6. Public health and prevention including migration
7. Active and healthy ageing

**HORIZONTAL themes**

8. Big data
9. eHealth, mHealth, ICT
10. Integration of care
11. Environment and health, green solutions and sustainability including climate change

**CROSS-CUTTING issues**

12. Social Sciences and Humanities, integration, inequalities, migration and ethics
13. Sex and gender differences in medicine
14. Commercialisation within “Health, Demographic Change and Well-being”
15. Encouraging stronger and successful involvement of EU-13
Health collaborative research
7 priorities for 2018–2020

1. Personalised medicine

2. Innovative health and care industry

3. Infectious diseases and improving global health

4. Innovative health, and care systems – Integration of care

5. Decoding the role of the environment for health and well-being

6. Digital transformation in Health and Care

7. Trusted Big Data solutions and Cybersecurity for Health and Care
Priority 1 – Personalised medicine

**AIM:** Delivering personalised health and care to benefit patients and citizens

**FOCUS:** complex disorders, human microbiome, rare diseases and data sharing for enabling personalised medicine, economic models, reinforcing international and regional collaboration

**POLICY DRIVERS:**

- Council conclusions on Personalised Medicine
- International Consortium on Personalised Medicine
- European Reference Networks
BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction, prevention and treatment of disease (€50.00M)

**Scope:** The aim is to achieve understanding of balanced states of health and on that basis to deliver personalised approaches and clinical tools for predicting and preventing diseases. Proposals should build on data from existing microbiome projects and integrate and use high quality microbiome, metabolome and other -omics data produced by large scale international initiative, such as the International Human Microbiome Consortium (IHMC).

Proposals requesting a contribution from the EU of between **EUR 10 and 15 million** would allow this specific challenge
BHC-04-2018: Rare Disease European Joint Programme Cofund (€55.00M)

Scope: The overall objective is to implement a European Joint Programme (EJP) Cofund for Rare Diseases which would create a research and innovation pipeline "from bench to bedside" ensuring rapid translation of research results into clinical applications and uptake in healthcare for the benefit of patients. The initiative should follow the policies and contribute to the objectives of the International Rare Diseases Research Consortium (IRDiRC). Participation of patient organisation should be encouraged in relevant activities of the EJP Cofund.

Proposals requesting a contribution from the EU of between 50 and EUR 55 million would allow these challenges to be addressed appropriately.
Actions proposed for the European Joint Programme on Rare Diseases

Key action 1
Transnational calls for proposals to fund rare diseases research.

Key action 2
Virtual platform for coordinated access, data exchange and repository facilities building on existing resources. Standards, analysis tools, links to care data. Pilots to ensure usefulness in clinical setting/ERNs.

Key action 3
Training and supporting on Data Management, Product development, Translational research etc for all stakeholders including patient organisations; Sharing best practices; Tech transfer facility towards industry.
BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities (€70.00M)

Scope: Proposals should identify and validate causative mechanisms (e.g. molecular, genetic, correlative, drug-drug interaction) combining mental and physical disorders through the integration of basic, pre-clinical and/or clinical research. Applicants should prove the relevance of the identified mechanisms for co-morbid development. Where pertinent, development of biomarkers and other technologies for diagnosis and monitoring of comorbid conditions in patients is encouraged. A purposeful exploitation of existing data, biobanks, registries and cohorts is expected, but does not exclude generation of new data. Sex and gender aspects, age, socio-economic, lifestyle and behavioural factors and any other non-health related.

Proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately.
BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders (€50.00M)

Scope: Research should aim to understand at systems level the pathophysiology of a disorder in groups of patients responding well or poorly to particular therapies and further develop combinatorial therapies tailored to the needs of individuals or stratified patient groups. Projects should focus on already available and/or authorised therapies and have access to standardized biobank samples derived from retrospective or currently running clinical studies. These patient samples should be re-analysed with modern high-throughput technologies. The existing and newly produced data should be integrated using systems approaches, which could combine sub-cellular/cellular and/or organ level in-silico models and network analysis as appropriate, and used to build more sophisticated computational frameworks to predict patient responses to combinatorial therapies. These predictions should be validated in pre-clinical and clinical studies taking into account sex and gender differences.

Proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately.
Personalised Medicine in Work Programme 2018–2020

BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches (€40.00M)

Scope: To build a collaboration of stakeholders in Europe and Canada in the domain of repositories storing and sharing human -omics data that will create a framework for long-term cooperation. This programme aims to enhance and standardise data deposition, curation and exchange procedures thus ensuring better data reuse and increased benefit to the scientific communities worldwide. The selected projects should build on the data quality metrics, standards and access policies developed by major international initiatives. This topic raises important issues of data sharing, privacy protection, informational right to self-determination and data security, which should be addressed from a legal, ethical as well as a social sciences perspective.

Proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately.
Priority 2 – Innovative health and care industry

**AIM:** Turn innovative knowledge and technologies into practical applications benefiting citizens, healthcare systems and businesses

**FOCUS:** Regenerative medicine, advanced therapeutics and regulatory science

**POLICY DRIVERS:**

[Upgrading the single market](#)
Innovative health and care industry in Work Programme 2018–2020

BHC-09-2018: Innovation platforms for advanced therapies of the future (€54.00M)

**Scope:** Building on European strengths, projects should create knowledge, testing and exploitation platforms around innovative concepts for advanced therapy development. Possible components could include studying the basic biology of the potential therapy and investigating its mode of action, proof of concept (*in vitro*, *in animal models* – where necessary - or first-in–man studies); safety, efficacy, characterisation, refinement and manufacturing of the product could be considered. Projects should also propose a business model for exploiting results and carry out appropriate outreach and public information activities. Examples of issues include gene delivery to cells, reducing off-target effects in gene therapy, immunogenicity of potential new therapies, cell homing and tracking, lack of adequate pre-clinical models, or responding to regulatory concerns, such as potency assays, product characterization, or bank-to-bank variability (non-exhaustive list for illustrative purposes only). Sex and gender differences should be investigated, where relevant. Potential ethical issues should be addressed.

Proposals requesting a contribution from the EU of between **EUR 12 and 15 million** would allow this specific challenge to be addressed appropriately.
Innovative health and care industry in Work Programme 2018–2020

BHC-07-2019: Regenerative medicine: from new insights to new applications (€50.00M)

**Scope:** Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups. Proposals should be based on new approaches such as genome editing or gene therapy, transdifferentiation or *in vivo* reprogramming, cell therapy and transplantation, 3D bioprinting, organoids or use of combined products. In all cases, proposals should explain in what way their approach is regenerative. Research on improved methods of tissue and organ transplantation is included on the condition that there is a clear regenerative step in the process. The project may focus on any step(s) on the innovation chain, from early testing and characterization of regenerative mechanisms to preclinical research, proof of concept or clinical trial. Sex and gender differences should be investigated, where relevant. Projects should include a section on the proposed therapy's exploitation potential, regulatory and commercialisation strategy and how it would be made available and delivered to patients.

Proposals requesting a contribution from the EU of between EUR 6 and 8 million would allow this specific challenge to be addressed appropriately.
BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis (€40.00M)

**Scope:** The objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for healthcare systems. This includes organisational, economical, technical and clinical aspects. It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes, tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decision-making and foster medical research and innovation. Transferability and cloud based NGS data analyses should be considered, as appropriate.

Proposals requesting a contribution from the EU of between EUR 9 and 11 million would allow this specific challenge to be addressed appropriately.
Priority 3 – Infectious diseases and improving global health

**AIM:** Fighting infectious diseases and the growing threat of antimicrobial resistance. Addressing the needs of the most vulnerable and the global increase in chronic diseases

**FOCUS:** Emerging infectious diseases, poverty and neglected diseases, stratified host-directed approaches to communicable diseases, maternal and child health, global collaboration on non-communicable diseases (cohorts, brain research, hypertension, diabetes, cancer)

**POLICY DRIVERS:**

European One Health Action Plan against Antimicrobial Resistance

Global Action Plan on antimicrobial resistance
BHC-15-2018: New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID) (€52.00M)

**Scope:** The topic **bridges the gap between preclinical and early clinical development of drugs and/or vaccines against neglected bacterial and parasitic diseases.** The proposed actions should focus on late preclinical (e.g. validation in animal models, toxicology, Good Manufacturing Practices (GMP) production, preparation of Investigational Medicinal Product Dossier) and early clinical (up to phase 1) development of already existing lead drug and vaccine candidates. **Multidisciplinary platforms bringing together academic and industry research teams, from European and disease-endemic countries, with the capacity to propose innovative solutions addressing several relevant pathogens** are encouraged. Sex and gender differences should be taken into account where relevant.

Proposals requesting a contribution from the EU of between **EUR 5 and 10 million** would allow this specific challenge to be addressed appropriately.

**Eligible neglected diseases** are: childhood diarrhoeal diseases, kinetoplastid diseases (human African Trypanosomiasis, leishmaniasis, Chagas disease) and helminth (Schistosomiasis, soil-transmitted helminthiases, food-borne trematodiases, filariasis, Onchocerciasis, taeniasis/cysticercosis, dracunculiasis, echinococcosis) diseases, as well as bacterial diseases like Buruli ulcer, leprosy, yaws and mycetoma. Neglected viral diseases are specifically excluded from this topic.
Infectious diseases and improving global health in Work Programme 2018–2020

BHC-21-2018: Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation (€10.00M)

Scope: Proposals should address one or more of the following subtopics:
1. **TB**: To investigate biomarkers or new diagnostic tests for early screening of risk groups for TB infection and identification of antimicrobial drug resistance.
2. **HIV**: To investigate the susceptibility to HIV and/or disease progression rate after infection, including various HIV subtypes and/or transmission clusters, and/or the development of adverse effects during antiretroviral therapy and concomitant diseases (comorbidities and/or co-infections, including with tuberculosis).
3. **HCV**: To evaluate the genetic determinants of the virus and the host, and comorbid conditions that can be involved in disease progression and create the basis for the development of future HCV treatment strategies.

Proposal should consider vulnerable groups and target populations, such as ageing subjects, injecting drug users and other social risk groups and include at least one participant from the Russian Federation. Sex and gender differences should be taken into account where relevant.

Proposal requesting an EU contribution between EUR 2 to 3 million would allow this specific challenge to be addressed appropriately.
BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases (€95.00M)

Scope: Proposals should test emerging concepts in drug and/or vaccine development in order to address the problem of antimicrobial drug resistance and to optimize therapeutic, curative or preventive measures against infectious diseases of major concern for Europe. Proposals should capitalize on knowledge of the role of host factors, immune-modulators or of host-pathogen interactions influencing disease outcome that can be utilized to strengthen the response to treatment or prevention measures. Differences in factors such as age, gender and genetic variation among the human population should be considered. The proposals should focus on late pre-clinical and/or clinical research, supporting proof of concept and selecting relevant biomarkers for clinical validation. They should take advantage of existing or newly established cohorts to help identify factors for predicting the course of the disease and its response to the intervention in stratified patients.

Proposals requesting a contribution from the EU of between EUR 6 and 10 million would allow this specific challenge to be addressed appropriately.
**Infectious diseases and improving global health in Work Programme 2018–2020**

**BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors (€30.00M)**

**Scope**: It is expected that proposals develop:
1. the technology to **allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing**;
2. the **innovative bio-informatics and modelling methodologies** that enable risk modelling and mapping;
3. the analytical **tools for early warning, risk assessment and monitoring of (re-emerging infectious disease threats**.

Proposals should be able to demonstrate the feasibility of such extended data mining for the purposes outlined above, as well as its European level added value.

Proposals should be **transdisciplinary** and ensure an integrated **One Health approach** by linking data from a wide range of relevant sources depending on the infectious disease threat. These may include human (e.g. community, hospital or laboratory health services) and animal health surveillance, health registries, microbial and viral genomic data.

Proposals requesting a contribution from the EU of between **EUR 12-15 million** would allow this specific challenge to be addressed appropriately.
BHC-16-2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes (€20.00M)

**Scope:** Proposals must focus on the scale-up of interventions at population level for hypertension and/or diabetes prevention and/or management in LMIC, and/or in vulnerable populations in HIC. Proposals addressing comorbidities with either hypertension or diabetes, including between them, are encouraged. Specific population age groups, sex and gender aspects, socio-economic, ethical, ethnic, cultural, lifestyle and behavioural factors and any other non-health related individual attributes should be taken into consideration where relevant.

Proposals requesting a contribution from the EU of between EUR 2 to 4 million would allow this specific challenge to be addressed appropriately.
BHC-18-2018: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC) (€25.00M)

**Scope:** Proposals must focus on translational and multidisciplinary research to identify specific patient groups in view of improving one or more of the following aspects: screening, early detection, diagnosis, and/or prognosis. Proposals must build on the diverse genetic backgrounds, risk factors, cancer incidence, geographical environment, and/or different healthcare models (including social care and volunteers) in European and CELAC countries. Specific population age groups, sex and gender aspects, socio-economic, ethical, ethnic, cultural, lifestyle and behavioural factors and any other non-health related individual attributes should be taken into consideration where relevant. Proposals may integrate molecular, behavioural, nutritional, clinical, social and environmental epidemiology data from cohorts; registries; biobanks; repositories; research infrastructures;

Proposals requesting a contribution from the EU of between **EUR 2 to 4 million** would allow this specific challenge to be addressed appropriately.
Infectious diseases and improving global health in Work Programme 2018–2020

BHC-19-2019: Implementation research for maternal and child health (€25.00M)

Scope: Proposals should focus on implementation research for improving maternal and child health with a focus on the first '1000 days' from pregnancy until two years of age. The research should take into account the specificities of different contexts and situations. The research should be integrated from different perspectives, e.g. recognising the interdependent relationship between mother and child; addressing prevention, health promotion and treatment; allowing for the specific needs of vulnerable groups (e.g. preterm infants, adolescents, migrants); addressing different concurrent pathologies; avoiding the creation of parallel or vertical programmes, etc.;. Research may cover physical and/or mental health, as well as communicable and non-communicable diseases. The integration of social sciences including gender analysis and the use of mixed methods research is strongly encouraged.

Proposals requesting an EU contribution between EUR 2 to 4 million would allow this specific challenge to be addressed appropriately.
Priority 4 – Innovative health and care systems – Integration of care

AIM: Develop effective, accessible and sustainable health interventions and integrated care systems

FOCUS: Mental health in the workplace, novel approaches for palliative care, implementation of personalised medicine, HTA, innovation in health care

POLICY DRIVERS:

Upgrading the single market

Cross-border healthcare Directive
BHC-23-2018: Novel patient-centred approaches for survivorship, palliation and/or end-of-life care (€44.00M)

Scope: Proposals should demonstrate the effectiveness and cost-effectiveness of new, improved or specifically adapted pharmacological and/or non-pharmacological interventions to either relieve symptoms (e.g. pain) and suffering caused by life-threatening non-communicable diseases (including disabilities), or serious late and long-term side effects of disease treatments in patients and survivors, or symptoms that occur at the end of life. Randomised clinical trials or observational studies of new or improved patient and/or family centred interventions, targeting children and/or adults, should be considered for this topic.

The proposals should address sex, gender, age and socio-economic factors in health and any other factors (e.g. ethical, familial, cultural considerations, including personal beliefs and religious perspectives, etc.) that could affect health equity.

Proposals requesting a contribution from the EU of between EUR 3 and 4 million would allow this specific challenge to be addressed appropriately.
BHC-22-2019: Mental health in the workplace (€30.00M)

Scope: Proposals should develop and implement intervention(s) that an employer/organization can take to promote good mental health and prevent mental illness in the workplace. Co-morbidities in mental and/or physical health should be addressed. Research should be multidisciplinary, including social sciences and the humanities. The stigma attached to mental ill health is important to consider as well as other social and cultural factors which may be relevant to improving the working environment. Mixed-methods research is encouraged. Proposals should involve key partners such as employers and employees in the private and public sector, policy makers, insurers, social partners and civil society in developing initiatives.

Proposals requesting a contribution from the EU of between EUR 2 to 4 million would allow this specific challenge to be addressed appropriately.
BHC-25-2019: Demonstration pilots for implementation of personalised medicine in healthcare (€60.00M)

**Scope:** The pilot projects should demonstrate the benefit for individuals as well as the implementability and economic viability of personalised medicine approaches in real life healthcare settings. The pilots should be tailored to the needs of citizens, making use of a wide variety of data and proposing prediction, prevention or treatment solutions, focussing on diseases with high burden to society (taking due account of sex/gender differences) and including multi-morbidity conditions if relevant. The use of big data approaches and high performance computing is encouraged. Applicants should address the health economic, ethical, legal and societal aspects of the proposed action. Projects with primary focus on cancer and rare diseases are excluded from the scope of this topic.

Proposals requesting a contribution from the EU of between EUR 18 and EUR 20 million would allow this specific challenge to be addressed appropriately.
**Innovative health and care systems**

**Integration of care**

in Work Programme 2018–2020

BHC-26-2018: HTA research to support evidence-based healthcare (€10.00M)

**Scope:** Proposals should **develop new or improved methodological approaches and frameworks, and foster methodological consensus-building**, to address all of the following areas:

1. Specific types or groups of health technologies; 2. Selected therapeutic areas; 3. Use of real-world data; 4. Implementation.

The proposed consortium should bring together partners with relevant expertise from e.g. academia, HTA bodies, regulators, centres of expertise for clinical research and care, scientific and medical learned societies, and organisations involved in developing evidence-based clinical guidelines and systematic reviews in healthcare. The consortium should also seek input from relevant stakeholders such as patients, technology developers, healthcare providers and payers. The composition of the consortium should ensure a broad geographical representation of European countries. Gender equality aspects should be taken into account in carrying out the relevant research objectives and activities.

Proposal requesting an EU contribution between **EUR 5 to 10 million** would allow this specific challenge to be addressed appropriately.
Priority 5 – Decoding the role of the environment, including climate change, for health and well-being

**AIM:** Improving the risk assessment of environment on health and well-being, and the related socio-economic impact and developing mitigation measures

**FOCUS:** New testing/screening methods to identify endocrine disrupting chemicals, the development of the 'human exposome' (to allow the assessment of lifelong environmental influences on individuals) and to set the priorities for a new research agenda

**POLICY DRIVERS:**

- The 7th Environment Action Programme (EAP)
- WHO Environment and Health Process (since 1989)
- REACH and EU related policies
- The UNFCCC Paris Agreement
BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (€52.00M)

**Scope:** In consultation with relevant regulatory bodies, research should improve and harmonise screening and testing protocols/strategies and hazard/risk assessments by developing better and faster tools, test methods or models. Focus should be on the most urgent regulatory needs, e.g., methods addressing the thyroid axis, developmental neurotoxicity, metabolic disorders, female reproduction and non-genotoxic carcinogenicity. Proposals should involve, in addition to academic researchers, regulatory agencies and other actors as appropriate. Proposers should consider sex and gender analysis when relevant.

Proposal requesting an EU contribution between **EUR 4 to 6 million** would allow this specific challenge to be addressed appropriately.
BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health (€50.00M)

**Scope:** Applicants should take advantage of the last decade's rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases. Proposals should use innovative approaches to the systematic and agnostic identification of the most important environmental risk factors for the development of major NCDs across the life course (including *in utero*), leading to preventive interventions at the individual, group or population level and contribute to sustainable healthcare. Well-designed retrospective epidemiological studies may be included and proposals may envisage the creation of a prospective Europe-wide exposomics cohort and biobank, integrating behavioural, socio-economic factors and clinical records.

Proposal requesting an EU contribution between **EUR 8 to 12 million** would allow this specific challenge to be addressed appropriately.
European human biomonitoring (HBM) initiative

- Strategic planning & coordination of national initiatives

- Creating a European joint programme for monitoring and scientific assessment of human exposures to chemicals and potential health impacts

- Coordinating HBM initiatives in Europe at national and EU level with special focus on a two way dialogue between policy and science in support of evidence based policy making

- Implementation through a Joint Programme Co-Fund

Preventing diseases
SC1-PM-05–2016: The European Human Biomonitoring Initiative
Call deadlines

Better Health and care, economic growth and sustainable health systems

BHC + HCO call topics
Calls open: 7 November 2017
Calls close: 18 April 2018

Exception
BHC-15-2018
Lump Sum Funding: a pilot topic
Calls open: 7 November 2017
First stage: 6 February 2018
Second stage: 4 September 2018

Digital transformation in Health and Care
Trusted digital solutions and Cybersecurity in Health and Care

DTH, HCC, and SU-TDS call topics
Calls open: 7 November 2017
Calls close: 24 April 2018
Inaugurazione della Sede Sapienza a Bruxelles, 6 giugno 2017
Principali servizi della sede di Bruxelles

• Relazioni con funzionari della Commissione e delle Agenzie Esecutive
• Supporto all’organizzazione di meeting di progetto e di eventi di disseminazione di progetti Sapienza
• Organizzazione di Eventi di matchmaking
• Supporto a docenti e ricercatori Sapienza impegnati in gruppi di lavoro e advisory group a Bruxelles
• Supporto amministrativo a gruppi di ricerca o coordinatori di progetti per la gestione ottimale dei rapporti con i funzionari comunitari
• Sinergia con gli enti di ricerca presenti nella stessa sede (CNR, INFN, ISS, APRE) per attività di networking e supporto del Sistema di ricerca italiano
1. Scelte strategiche e focus di intervento

- Settorializzazione degli interventi 2017, scegliendo un punto di partenza: Health, Social Sciences and Humanities

- Promozione della interdisciplinarietà e della collaborazione progettuale tra Dipartimenti

Visite, incontri informativi e formativi, a partire dalle macro aree tematiche individuate, presso i Dipartimenti con gruppi di ricerca, con supporto organizzativo e presenza dei Referenti ricerca dei Dipartimenti

Contributo alla mappatura delle competenze e delle esigenze dei Dipartimenti

NEXT STEP
Definizione e organizzazione di un percorso formativo mirato di progettazione
2. Strumenti informativi personalizzati

Informative mirate a gruppi specifici di ricerca su call di prossima pubblicazione, anticipazioni di Work Programme

Strumenti di raccordo ricercatori-amministrazione centrale: Idee per H2020
3. Risorse interne per stimolare la progettualità europea

Finanziamenti di Ateneo per la ricerca scientifica, a valere su risorse interne

Sapienza, Bandi di Ateneo 2017 – Progetti H2020
«La misura è volta a stimolare la partecipazione ai progetti europei sostenendo i gruppi di ricerca che abbiano presentato proposte di elevata qualità a livello internazionale [...]. I finanziamenti sono riservati a gruppi di ricerca che abbiano presentato progetti collaborativi come Università La Sapienza nell’ambito del Programma Quadro per la Ricerca Europea Horizon 2020 che siano stati oggetto di positiva valutazione, ma non siano stati ammessi al finanziamento.»

Sapienza, Bandi di Ateneo 2016 – Progetti interdisciplinari
«I Progetti Interdisciplinari si configurano come un primo studio di fattibilità per la preparazione di proposte che possano essere successivamente finanziate nell’ambito di Horizon 2020 e di fondi strutturali. ...Le proposte si devono basare sulla presenza già consolidata presso l’Ateneo di competenze, strutture e personale che assicurino una massa critica in grado di partecipare a collaborazioni internazionali.»
Contatti

Ciro Franco
Capo Ufficio Fund Raising e Progetti
Email ciro.franco@uniroma1.it

Tel. 06 4969 0259 Interno 30259

Sito web:
http://www.uniroma1.it/ricerca/finanziamenti
GRAZIE PER L’ATTENZIONE

Horizon 2020

Giornate Nazionali

Work Programme 18-20

Roma, 15 Dicembre 2017

Sapienza Università di Roma, Aula Magna, Piazzale Aldo Moro, 5
## Health research in Horizon 2020

<table>
<thead>
<tr>
<th>Collaborative health research (SC1)</th>
<th>Public-private partnership</th>
<th>Frontier research</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support to innovation</strong></td>
<td>Modelling &amp; predictive (neuro)sciences</td>
<td><strong>Research Education Innovation</strong></td>
</tr>
<tr>
<td><strong>SME Instrument</strong></td>
<td>Human Brain Project</td>
<td><strong>Public-public partnerships</strong></td>
</tr>
<tr>
<td><strong>ESFRI</strong> European Strategy Forum on Research Infrastructures</td>
<td>InnovFin EU Finance for Innovators</td>
<td><strong>Deployment of innovative solutions</strong></td>
</tr>
<tr>
<td><strong>Loans for de-risking R&amp;I</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Programmes**
- EIC Accelerator
- EIT Health
- EIT Digital
- EDF
- IMPERATIVE
- EDCTP
- AAL Programme
- JUICe
- JPI AMR
These objectives implement the EU's commitment at international level and at EU level in particular:

- the [2030 Agenda for Sustainable Development and its Sustainable Development Goals](https://www.un.org/sustainabledevelopment/2030-agenda/),
- the COP21 and the goals of [the Ostrava declaration on environment and health](https://www.ostrava2015.org/),
- the [Commission Communication on upgrading the single market](https://ec.europa.eu/commission/2020/health_en) (and its proposed health technology assessments initiative), and
7 priorities implemented via SC1 Work Programme 2018–2020 through 3 Calls for proposals

**Call 'Better Health and care, economic growth and sustainable health systems'**
5 main priorities & 32 topics

**Call 'Digital transformation in Health and Care'**
13 topics

**Call 'Trusted digital solutions and Cybersecurity in Health and Care'**
3 topics

**Other Actions 2018–2019**
7 items

approx. €2 billion